Shopping Cart 0
Cart Subtotal
USD 0

EpiCast Report: Rheumatoid Arthritis-Epidemiology Forecast to 2025

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 11985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

EpiCast Report: Rheumatoid Arthritis-Epidemiology Forecast to 2025

Summary

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the body's immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life.

In the 8MM, GlobalData epidemiologists forecast that the diagnosed incident cases of RA will increase from 195,592 cases in 2015 to 216,467 cases in 2025, at an Annual Growth Rate (AGR) of 1.07%. The US will have the highest number of diagnosed incident cases of RA among the 8MM throughout the forecast period, while Spain will have the lowest.

In the 8MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of RA will increase from 4,354,194 cases in 2015 to 4,931,572 cases in 2025, at an AGR of 1.33%. The US will have the highest number of diagnosed prevalent cases of RA among the 8MM throughout the forecast period, while Australia will have the lowest.

In the 8MM, GlobalData epidemiologists forecast that the total prevalent cases of RA will increase from 6,137,523 cases in 2015 to 6,971,304 cases in 2025, at an AGR of 1.36%. The US will have the highest number of total prevalent cases of RA among the 8MM throughout the forecast period, while Australia will have the lowest.

GlobalData epidemiologists utilized data from county-specific studies published in peer-reviewed journals as well as data obtained from primary research. In order to ensure comparability of the incidence and prevalence across markets, GlobalData epidemiologists used sources that provided the diagnosed incidence and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria for the classification of RA.

Scope

The Rheumatoid Arthritis (RA) EpiCast Report provides an overview of the risk factors and global trends of RA in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, and total prevalent cases of RA segmented by age and sex in these eight markets. The diagnosed prevalent cases of RA are further segmented by severity in the 8 MM for the forecast period.

The RA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The RA EpiCast report will allow you to

Develop business strategies by understanding the trends shaping and driving the global RA market.

Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RA therapeutics in each of the markets covered.

Identify the percentage of diagnosed prevalent cases of RA by severity.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 6

1.2 List of Figures 7

2 Epidemiology 8

2.1 Disease Background 8

2.2 Risk Factors and Comorbidities 9

2.3 Global Trends 9

2.3.1 Diagnosed Incidence 11

2.3.2 Prevalence 12

2.4 Forecast Methodology 14

2.4.1 Sources Used 14

2.4.2 Forecast Assumptions and Methods 18

2.4.3 Sources Not Used 28

2.5 Epidemiological Forecast for RA (2015-2025) 28

2.5.1 Diagnosed Incident Cases 28

2.5.2 Diagnosed Prevalent Cases 35

2.5.3 Total Prevalent Cases 43

2.6 Discussion 50

2.6.1 Epidemiological Forecast Insight 50

2.6.2 Limitations of the Analysis 51

2.6.3 Strengths of the Analysis 52

3 Appendix 53

3.1 Bibliography 53

3.2 Physicians and Specialists Included in this Study 56

3.3 About the Authors 58

3.3.1 Epidemiologist 58

3.3.2 Reviewers 58

3.3.3 Global Director of Therapy Analysis and Epidemiology 59

3.4 About GlobalData 60

3.5 About EpiCast 60

3.6 Disclaimer 61


List Of Figure

1.2 List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of RA, Ages ?18 Years, Both Sexes, N, 2015-2025 30

Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N, 2015 32

Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ?18 Years, N, 2015 34

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RA, Ages ?18 Years, Cases per 100,000 Population, 2015 35

Figure 5: 8MM, Diagnosed Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 37

Figure 6: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N, 2015 39

Figure 7: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ?18 Years, N, 2015 41

Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of RA, Ages ?18 Years, %, 2015 42

Figure 9: 8MM, Diagnosed Prevalent Cases of RA by Severity, Both Sexes, Ages ?18 Years, N, 2015 43

Figure 10: 8MM, Total Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 45

Figure 11: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N, 2015 47

Figure 12: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ?18 Years, N, 2015 49

Figure 13: 8MM, Age-Standardized Total Prevalence of RA, Ages ?18 Years, N, 2015 50


List Of Table

1.1 List of Tables

Table 1: Risk Factors and Comorbidities of RA 9

Table 2: 1987 ACR Diagnostic Criteria for RA 10

Table 3: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA 15

Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA 16

Table 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA 17

Table 6: 8MM, Sources Used to Forecast Severity Segmentation of the Diagnosed Prevalent Cases of RA 18

Table 7: 8MM, Sources Not Used in the Epidemiological Analysis of RA 28

Table 8: 8MM, Diagnosed Incident Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 29

Table 9: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N (Row %), 2015 31

Table 10: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ?18 Years, N (Row %), 2015 33

Table 11: 8MM, Diagnosed Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 36

Table 12: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N (Row %), 2015 38

Table 13: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ?18 Years, N (Row %), 2015 40

Table 14: 8MM, Total Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 44

Table 15: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2015 46

Table 16: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ?18 Years, N (Row %), 2015 48

Table 17: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2016 57

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

EpiCast Report: Rheumatoid Arthritis-Epidemiology Forecast to 2025

Summary

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the body's immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life.

In the 8MM, GlobalData epidemiologists forecast that the diagnosed incident cases of RA will increase from 195,592 cases in 2015 to 216,467 cases in 2025, at an Annual Growth Rate (AGR) of 1.07%. The US will have the highest number of diagnosed incident cases of RA among the 8MM throughout the forecast period, while Spain will have the lowest.

In the 8MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of RA will increase from 4,354,194 cases in 2015 to 4,931,572 cases in 2025, at an AGR of 1.33%. The US will have the highest number of diagnosed prevalent cases of RA among the 8MM throughout the forecast period, while Australia will have the lowest.

In the 8MM, GlobalData epidemiologists forecast that the total prevalent cases of RA will increase from 6,137,523 cases in 2015 to 6,971,304 cases in 2025, at an AGR of 1.36%. The US will have the highest number of total prevalent cases of RA among the 8MM throughout the forecast period, while Australia will have the lowest.

GlobalData epidemiologists utilized data from county-specific studies published in peer-reviewed journals as well as data obtained from primary research. In order to ensure comparability of the incidence and prevalence across markets, GlobalData epidemiologists used sources that provided the diagnosed incidence and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria for the classification of RA.

Scope

The Rheumatoid Arthritis (RA) EpiCast Report provides an overview of the risk factors and global trends of RA in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases, diagnosed prevalent cases, and total prevalent cases of RA segmented by age and sex in these eight markets. The diagnosed prevalent cases of RA are further segmented by severity in the 8 MM for the forecast period.

The RA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The RA EpiCast report will allow you to

Develop business strategies by understanding the trends shaping and driving the global RA market.

Quantify patient populations in the global RA market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RA therapeutics in each of the markets covered.

Identify the percentage of diagnosed prevalent cases of RA by severity.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 6

1.2 List of Figures 7

2 Epidemiology 8

2.1 Disease Background 8

2.2 Risk Factors and Comorbidities 9

2.3 Global Trends 9

2.3.1 Diagnosed Incidence 11

2.3.2 Prevalence 12

2.4 Forecast Methodology 14

2.4.1 Sources Used 14

2.4.2 Forecast Assumptions and Methods 18

2.4.3 Sources Not Used 28

2.5 Epidemiological Forecast for RA (2015-2025) 28

2.5.1 Diagnosed Incident Cases 28

2.5.2 Diagnosed Prevalent Cases 35

2.5.3 Total Prevalent Cases 43

2.6 Discussion 50

2.6.1 Epidemiological Forecast Insight 50

2.6.2 Limitations of the Analysis 51

2.6.3 Strengths of the Analysis 52

3 Appendix 53

3.1 Bibliography 53

3.2 Physicians and Specialists Included in this Study 56

3.3 About the Authors 58

3.3.1 Epidemiologist 58

3.3.2 Reviewers 58

3.3.3 Global Director of Therapy Analysis and Epidemiology 59

3.4 About GlobalData 60

3.5 About EpiCast 60

3.6 Disclaimer 61


List Of Figure

1.2 List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of RA, Ages ?18 Years, Both Sexes, N, 2015-2025 30

Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N, 2015 32

Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ?18 Years, N, 2015 34

Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RA, Ages ?18 Years, Cases per 100,000 Population, 2015 35

Figure 5: 8MM, Diagnosed Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 37

Figure 6: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N, 2015 39

Figure 7: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ?18 Years, N, 2015 41

Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of RA, Ages ?18 Years, %, 2015 42

Figure 9: 8MM, Diagnosed Prevalent Cases of RA by Severity, Both Sexes, Ages ?18 Years, N, 2015 43

Figure 10: 8MM, Total Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 45

Figure 11: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N, 2015 47

Figure 12: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ?18 Years, N, 2015 49

Figure 13: 8MM, Age-Standardized Total Prevalence of RA, Ages ?18 Years, N, 2015 50


List Of Table

1.1 List of Tables

Table 1: Risk Factors and Comorbidities of RA 9

Table 2: 1987 ACR Diagnostic Criteria for RA 10

Table 3: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA 15

Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA 16

Table 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA 17

Table 6: 8MM, Sources Used to Forecast Severity Segmentation of the Diagnosed Prevalent Cases of RA 18

Table 7: 8MM, Sources Not Used in the Epidemiological Analysis of RA 28

Table 8: 8MM, Diagnosed Incident Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 29

Table 9: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, N (Row %), 2015 31

Table 10: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ?18 Years, N (Row %), 2015 33

Table 11: 8MM, Diagnosed Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 36

Table 12: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, N (Row %), 2015 38

Table 13: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ?18 Years, N (Row %), 2015 40

Table 14: 8MM, Total Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2015-2025 44

Table 15: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2015 46

Table 16: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ?18 Years, N (Row %), 2015 48

Table 17: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2016 57

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com